CNS

Brii Biosciences announced $155 million last week in Series C financing.

The press release said the Sino-American biotech will use the proceeds to fund clinical studies and research for its therapies for hepatitis B, Covid-19, multi-drug resistant Gram-negative bacterial infection and HIV, as well as its central nervous system disease program.